The enlargement, in which the company invested approximately 100 million euros ($107 million), bundles capacity for final product inspection and logistics in one cutting-edge site. By finalizing the second construction stage of the site that was initially put into operation five years ago, the CDMO now offers more than double the capacity for state-of-the-art quality control, cold-storage and room-temperature storage. Given the increasing industry-specific requirements emanating from customer and regulatory side, the company now provides even more efficient and flexible supply chain processes.
The expanded Center, referred to as Ravensburg Vetter West, is located on approximately 50,000 square meters (538,000 square feet) of floor space and offers a 35,000 pallet warehouse capacity for storing pharmaceuticals in refrigeration or room temperature conditions. The capacities for chest freezers, incubation chambers, and constant climate chambers have also been increased, as have the visual inspection capacities of filled units which can be realized in either manual or automatic mode. This allows Vetter to react with greater flexibility to individual market and customer needs.
The center also contains a support materials warehouse with corresponding safety installations as well as a new packaging-check laboratory and the company’s central archive. Additionally, the number of office workspaces were increased. By the end of 2017, the CDMO will relinquish its existing Holbeinstrasse site for visual inspection and logistics. Its employees and departments will gradually be relocated to Ravensburg Vetter West, resulting in a working staff of approximately 800 employees.
Vetter is a global leader in the fill and finish of aseptically prefilled syringe systems, cartridges and vials. Headquartered in Ravensburg, Germany, the company operates production facilities in Germany and the United States, as well as sales offices in Singapore and Tokyo, Japan. The contract development and manufacturing organization (CDMO) is an innovative solution provider serving small, midsize, and the top 10 (bio-)pharmaceutical companies. Its portfolio spans state-of-the-art manufacturing from early clinical development through commercial filling and final packaging of parenteral drugs. Known for quality, the company of approximately 4,100 employees offers a foundation of experience spanning more than 35 years, including dozens of customer product approvals for novel compounds. More than 70% of Vetter’s active projects are biologics, and Vetter currently manufactures five of the world’ top 10. The CDMO is also committed to patient safety and compliance with user friendly solutions such as Vetter-Ject® , as well as its dualchamber syringe Vetter Lyo-Ject® and cartridge system V-LK® . Visit www.vetter-pharma.com .
Vetter Pharma International GmbH
Press Spokesperson / Specialist External Communications
Eywiesenstrasse 5 88212 Ravensburg ermany
Phone: +49 (0)751-3700-3729